Modality
Radioligand
MOA
CDK4/6i
Target
PLK4
Pathway
T-cell
MSMCCPsA
Development Pipeline
Preclinical
~Dec 2019
→ ~Mar 2021
Phase 1
~Jun 2021
→ ~Sep 2022
Phase 2
~Dec 2022
→ ~Mar 2024
Phase 3
~Jun 2024
→ ~Sep 2025
NDA/BLA
Dec 2025
→ Nov 2027
NDA/BLACurrent
NCT07193018
2,660 pts·MCC
2025-12→2027-11·Not yet recruiting
2,660 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-191.6y awayPh3 Readout· MCC
Trial Timeline
2026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2027-11-19 · 1.6y away
MCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07193018 | NDA/BLA | MCC | Not yet recr... | 2660 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| NBI-3153 | Neurocrine | Approved | Aβ |